GlassScriptPhysician profile
Kaitlin Mostoller
NPI 1316594609
$10,035.71
in general payments reported to CMS, 2019-2025
47 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,840 · 2022: $2,079 · 2023: $1,624 · 2024: $2,157 · 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,966 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,966.25 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,739.45 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,085.18 | 2021-2025 | Nuplazid |
| Biogen, INC. | $442.61 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Emd Serono, INC. | $371.38 | 2022-2025 | Mavenclad |
| Lundbeck LLC | $368.72 | 2021-2025 | Vyepti |
| Tg Therapeutics, INC. | $359.89 | 2023-2025 | |
| Celgene Corporation | $352.77 | 2021-2024 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $331.88 | 2021 | |
| Sk Life Science, INC. | $318.96 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $318.74 | 2021-2025 | Austedo Xr, Ajovy |
| Jazz Pharmaceuticals INC. | $291.19 | 2022-2025 | Xywav |
| Biohaven Pharmaceutical Holding Company LTD. | $278.23 | 2022 | |
| Lilly USA, LLC | $253.86 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Novartis Pharmaceuticals Corporation | $237.69 | 2021-2025 | |
| Amgen INC. | $237.06 | 2021-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $230.71 | 2024-2025 | Ingrezza |
| Amneal Pharmaceuticals LLC | $216.39 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Pfizer INC. | $210.58 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $185.26 | 2022-2025 | Ponvory, Hetlioz |
| Janssen Pharmaceuticals, INC | $176.10 | 2021-2022 | |
| Argenx US, INC. | $173.02 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $166.10 | 2021-2025 | Rystiggo, Briviact, Nayzilam |
| Genentech USA, INC. | $158.11 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Harmony Biosciences LLC | $157.26 | 2022 | |
| Genzyme Corporation | $144.38 | 2021-2023 | |
| Eisai INC. | $140.76 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $133.11 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $120.42 | 2022-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $117.72 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $112.01 | 2025 | Lumryz |
| Cala Health, INC. | $86.38 | 2022 | |
| Avanir Pharmaceuticals, INC. | $72.80 | 2022 | |
| Supernus Pharmaceuticals, INC. | $65.39 | 2021-2022 | |
| Axsome Therapeutics, INC. | $48.65 | 2025 | Symbravo |
| Mdd US Operations, LLC | $45.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $45.44 | 2023-2024 | Wainua |
| Kyowa Kirin, INC. | $42.11 | 2023-2024 | Nourianz |
| Almatica Pharma LLC | $31.38 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.71 | 2021 | |
| Currax Pharmaceuticals LLC | $26.88 | 2021 | |
| Neurelis, INC. | $19.67 | 2021 | |
| Acorda Therapeutics, INC | $19.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.84 | 2023 | Quviviq |
| Ani Pharmaceuticals, INC. | $15.46 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $14.89 | 2023 | Gammagard |
| Avion Pharmaceuticals | $14.13 | 2022 | |
| Allergan, INC. | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Mostoller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.